297 related articles for article (PubMed ID: 29680938)
1. Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.
Dispenza MC; Bochner BS
Curr Hematol Malig Rep; 2018 Jun; 13(3):191-201. PubMed ID: 29680938
[TBL] [Abstract][Full Text] [Related]
2. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
Helbig G; Kyrcz-Krzemień S
Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
[TBL] [Abstract][Full Text] [Related]
4. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
5. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
6. Cough in hypereosinophilic syndrome: case report and literature review.
Xie J; Zhang J; Zhang X; Zhang Q; Chung KF; Wang C; Lai K
BMC Pulm Med; 2020 Apr; 20(1):90. PubMed ID: 32293378
[TBL] [Abstract][Full Text] [Related]
7. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang FL; Klion AD
J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes.
Stella S; Massimino M; Manzella L; Pennisi MS; Tirrò E; Romano C; Vitale SR; Puma A; Tomarchio C; Gregorio SD; Palumbo GA; Vigneri P
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418988
[TBL] [Abstract][Full Text] [Related]
9. [Hypereosinophilic syndromes: pathogenic and therapeutic up-to-date].
Kahn JE; Grandpeix-Guyodo C; Ackermann F; Charles P; Legrand F; Blétry O
Rev Med Interne; 2010 Apr; 31(4):268-76. PubMed ID: 20303627
[TBL] [Abstract][Full Text] [Related]
10. Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
Kuang FL; Khoury P; Weller PF; Wechsler ME; Klion AD
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2666-2671. PubMed ID: 37507068
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
12. How I treat hypereosinophilic syndromes.
Klion AD
Blood; 2015 Aug; 126(9):1069-77. PubMed ID: 25964669
[TBL] [Abstract][Full Text] [Related]
13. The hypereosinophilic syndromes: still more heterogeneity.
Gleich GJ; Leiferman KM
Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
[TBL] [Abstract][Full Text] [Related]
14. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
15. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
16. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of the hypereosinophilic syndromes.
Cogan E; Roufosse F
Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
[TBL] [Abstract][Full Text] [Related]
18. How I treat hypereosinophilic syndromes.
Klion AD
Blood; 2009 Oct; 114(18):3736-41. PubMed ID: 19692700
[TBL] [Abstract][Full Text] [Related]
19. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
20. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
